Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Almasilate→

Almasilate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
71205-22-6
Molecular formula
Al2H2MgO9Si2
Molecular weight
280.45 g/mol
Drug class
Aluminium-magnesium silicate antacid and adsorbent
Mechanism of action
Neutralises gastric acid and adsorbs selected luminal substances through its mineral surface and acid-neutralising capacity; it acts locally within the gastrointestinal tract.
Indications / reported uses
  • Symptomatic relief of gastric hyperacidity, heartburn and dyspepsia in countries where almasilate-containing oral products are authorised

Sources: NLM MeSH — Almasilate · PubMed — Almasilate antacid · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Almasilate Environmental Risk Assessment (ERA) (the Almasilate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.